Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out

被引：2
|
作者：
Schmitt, Andreas Michael [1 ]
Larkin, James [2 ]
Patel, Sapna P. [3 ]
机构：
[1] Univ Hosp Basel, Dept Med Oncol, Basel, Switzerland
[2] Royal Marsden Hosp NHS Fdn Trust, Dept Med Oncol, London, England
[3] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 02期
关键词：
ANTIBODY;
D O I：
10.1200/JCO-24-01572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil
    Sorroche, Bruna Pereira
    Teixeira, Renan de Jesus
    Pereira, Caio Augusto Dantas
    Santana, Iara Viana Vidigal
    Vujanovic, Lazar
    Vazquez, Vinicius de Lima
    Arantes, Lidia Maria Rebolho Batista
    DIAGNOSTICS, 2023, 13 (06)
  • [42] Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma
    Wang, Zeping
    Zou, Xiaojing
    Wang, Haiyan
    Hao, Zhihui
    Li, Gebin
    Wang, Shuaiyu
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [43] Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou, Markella
    Zarganes-Tzitzikas, Tryfon
    Magiera-Mularz, Katarzyna
    Holak, Tad A.
    Domling, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (18) : 4840 - 4848
  • [44] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [45] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [46] Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.
    Pal, Sumanta K.
    Vanderwalde, Ari M.
    Szeto, Christopher
    Benz, Stephen Charles
    Sanborn, John Zachary
    Vaske, Charles Joseph
    Reddy, Sandeep K.
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1
    Hacking, Sean
    Chavarria, Hector
    Jin, Cao
    Perry, Alexander
    Nasim, Mansoor
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (04)
  • [48] Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade
    Koopmans, Iris
    Hendriks, Mark A. J. M.
    van Ginkel, Robert J.
    Samplonius, Douwe F.
    Bremer, Edwin
    Helfrich, Wijnand
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (11) : 2343 - +
  • [49] A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint
    Lu, Huijiao
    Liang, Jiahua
    He, Xue
    Ye, Huabin
    Ruan, Chuangdong
    Shao, Hongwei
    Zhang, Rongxin
    Li, Yan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [50] Chronic immune-related toxicity: a still underrecognized complication of PD-L1 inhibition
    Engel, J.
    Joiner, F.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2025, 369
12345